On-track to initiate Phase 2 trial in Q1
2023
NEW
YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused
biopharmaceutical company, today announced that the U.S. Food
and Drug Administration (FDA) has accepted an Investigational New
Drug (IND) application for the company's HT-001 therapeutic for
the treatment for rash and skin disorders associated with
epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR
inhibitors are critical therapeutic agents for the treatment of
non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal
cancer, squamous-cell carcinoma of the head and neck, and breast
cancer.
![(PRNewsfoto/Hoth Therapeutics Inc.) (PRNewsfoto/Hoth Therapeutics Inc.)](https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg)
"We are excited to begin our trial and bring hope to patients
who are suffering. With no specific treatment currently
approved for the treatment of skin toxicities associated with EGFRi
therapies, this trial brings us one step closer to a new treatment
option for underserved cancer patients," said Robb Knie, CEO
of Hoth Therapeutics, Inc. "We look forward to advancing HT-001
into the clinical phase as we believe that this novel therapeutic
will be a key treatment in the onco-dermatology space. We
anticipate beginning our Phase 2a trial in Q1 of 2023.
About Hoth Therapeutics,
Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical
company dedicated to developing innovative, impactful, and
ground-breaking treatments with a goal to improve patient quality
of life. We are a catalyst in early-stage pharmaceutical research
and development, elevating drugs from the bench to pre-clinical and
clinical testing. Utilizing a patient-centric approach, we
collaborate and partner with a team of scientists, clinicians, and
key opinion leaders to seek out and investigate therapeutics that
hold immense potential to create breakthroughs and diversify
treatment options. To learn more, please visit
https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations which may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws, and are subject to
substantial risks, uncertainties and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates
Hoth may develop, and the labeling under any approval Hoth may
obtain; the timing and costs of clinical trials, the timing and
costs of other expenses; market acceptance of Hoth's products; the
ultimate impact of the current Coronavirus pandemic, or any other
health epidemic, on Hoth's business, its clinical trials, its
research programs, healthcare systems or the global economy as a
whole; Hoth's intellectual property; Hoth's reliance on third party
organizations; Hoth's competitive position; Hoth's industry
environment; Hoth's anticipated financial and operating results,
including anticipated sources of revenues; Hoth's assumptions
regarding the size of the available market, benefits of Hoth's
products, product pricing, timing of product launches; management's
expectation with respect to future acquisitions; statements
regarding Hoth's goals, intentions, plans and expectations,
including the introduction of new products and markets; and Hoth's
cash needs and financing plans. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. You should not place undue
reliance on these forward-looking statements, which include words
such as "could," "believe," "anticipate," "intend," "estimate,"
"expect," "may," "continue," "predict," "potential," "project" or
similar terms, variations of such terms or the negative of those
terms. Although Hoth believes that the expectations reflected in
the forward-looking statements are reasonable, Hoth cannot
guarantee such outcomes. Hoth may not realize its expectations, and
its beliefs may not prove correct. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including, without
limitation, market conditions and the factors described in the
section entitled "Risk Factors" in Hoth's most recent Annual Report
on Form 10-K and Hoth's other filings made with the U.S. Securities
and Exchange Commission. All such statements speak only as of the
date of this press release. Consequently, forward-looking
statements should be regarded solely as Hoth's current plans,
estimates, and beliefs. Hoth cannot guarantee future results,
events, levels of activity, performance or achievements. Hoth does
not undertake and specifically declines any obligation to update or
revise any forward-looking statements to reflect new information,
future events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by applicable
law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-fda-acceptance-of-ind-application-for-ht-001-for-the-treatment-of-cancer-disorders-associated-with-epidermal-growth-factor-receptor-egfr-inhibitor-therapy-301711012.html
SOURCE Hoth Therapeutics, Inc.